Silvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.
Am J Public Health. 2024 Nov;114(S8):S694-S697. doi: 10.2105/AJPH.2024.307729.
To characterize cannabis-related disorder medical encounter trends in the US Medicare population during 2017 to 2022. We conducted a descriptive study, which included 56 624 432 beneficiaries aged 65 years or older and 10 247 953 aged 18 to 64 years with disability. All were continuously enrolled in Medicare (Fee-for-Service or Advantage) for 183 or more days before the first day of the calendar year. We identified cannabis-related disorder encounters using diagnosis codes and computed annual encounter rates per 10 000 beneficiaries. We used the Mann-Kendall test to analyze trends over time. Annual cannabis-related disorder encounter trends among beneficiaries aged 65 years or older ranged from 15.9 (95% confidence interval [CI] = 15.8, 16.0) to 39.3 (95% CI = 39.1, 39.5) per 10 000. Rates among beneficiaries aged 18 to 64 years with disability ranged from 274.8 (95% CI = 273.6, 276.0) to 373.7 (95% CI = 372.3, 375.2) per 10 000. Rates increased over time across both groups, with average annual increases of 4.3 (95% CI = 3.3, 5.3; = .01) and 17.1 (95% CI = 11.0, 23.2; = .02) per 10 000, respectively. Further work is needed to explore the impact of coexisting medical conditions on outcomes that result from cannabis-related disorders. (. 2024;114(S8):S694-S697. https://doi.org/10.2105/AJPH.2024.307729).
为了描述 2017 年至 2022 年期间美国医疗保险人群中与大麻相关的障碍医疗就诊趋势。我们进行了一项描述性研究，其中包括 56624432 名 65 岁或以上的受益人和 10247953 名 18 至 64 岁的残疾受益人的数据。所有参与者在每个日历年前的 183 天或以上持续参加医疗保险（按服务付费或优势）。我们使用诊断代码识别与大麻相关的障碍就诊，并计算每 10000 名受益人的年度就诊率。我们使用曼肯德尔检验来分析随时间的趋势。65 岁或以上的受益人的年度与大麻相关的障碍就诊趋势范围为 15.9（95%置信区间[CI] = 15.8, 16.0）至 39.3（95%CI = 39.1, 39.5）每 10000。残疾 18 至 64 岁的受益人的比率范围为 274.8（95%CI = 273.6, 276.0）至 373.7（95%CI = 372.3, 375.2）每 10000。两组的比率都随着时间的推移而增加，平均每年分别增加 4.3（95%CI = 3.3, 5.3； =.01）和 17.1（95%CI = 11.0, 23.2； =.02）每 10000。（ 2024；114(S8)：S694-S697。https://doi.org/10.2105/AJPH.2024.307729）。
